Join
Live feed
·
PRReleasevia Quantisnow
Aldeyra Therapeutics Inc. logo

Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis

ByQuantisnow·Wall Street's wire, on your screen.
ALDX· Aldeyra Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALDX (Aldeyra Therapeutics Inc.) and more on Quantisnow.